Log In
Print this Print this

voxilaprevir (GS-9857)

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionPan-genotypic HCV NS3/NS4A protease inhibitor
Molecular Target HCV NS3 protease
Mechanism of ActionHCV NS3 protease inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat chronic HCV infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today